ARTICLE | Company News
Ablynx N.V. (Euronext:ABLX) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to eight multi-specific Nanobodies to treat undisclosed immune-mediated inflammatory diseases.
Sanofi is responsible for the candidates' development and commercialization. Ablynx will receive €23 million ($26.3 million) up front and about €8 million ($9.1 million) in research funding. The biotech is eligible for €2.4 billion ($2.7 billion) in milestones, plus tiered, low double-digit royalties...